Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Amino Acid Formula Clear all
Completed Not applicable Interventional

A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy

NCT00664768
View directory record Official record
Conditions
Cow Milk Allergy
Interventions
Neocate Infant, new Neocate
Dietary Supplement
Lead sponsor
Nutricia North America
Industry
Eligibility
1 Day to 8 Months
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Chandler, Arizona • Tucson, Arizona • Bentonville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

NCT01836575
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
Instituto Nacional de Cancer, Brazil
Government
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

NCT01620190
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
12
States / cities
Anchorage, Alaska • Bozeman, Montana • Kennewick, Washington + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00874107
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Imprime PGG® Injection, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Fayetteville, Arkansas • Canton, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Not applicable Interventional Results available

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

NCT01312272
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00666692
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

NCT00396097
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Genotropin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 10 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
43
States / cities
Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Not applicable Interventional

Nutritional Management of Infants With Chronic Diarrhea

NCT01820494
View directory record Official record
Conditions
Growth and Tolerance Infant Study
Interventions
Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 12 Months
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

NCT02657434
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
26
States / cities
Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 26, 2026, 10:32 AM EDT
Completed No phase listed Observational

Fiber Formula Study Among Radiation Oncology Patients

NCT00888147
View directory record Official record
Conditions
Constipation
Interventions
Fiber containing tube feeding formula
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 26, 2026, 10:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Bevacizumab for Recurrent Ependymoma

NCT01295944
View directory record Official record
Conditions
Ependymoma, Anaplastic Ependymoma
Interventions
Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Not applicable Interventional

Infants With Protein Sensitive Colitis

NCT01813526
View directory record Official record
Conditions
Protein Sensitive Colitis
Interventions
Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 6 Months
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 26, 2026, 10:32 AM EDT
Not yet recruiting Not applicable Interventional

Palatable Elemental Diet for Gastrointestinal Symptoms in Chronic Pancreatitis

NCT07559448
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Palatable Elemental Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 26, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 26, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional Results available

Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

NCT04163432
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic
Interventions
Durvalumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 26, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional

Impact of Infant Formula on Resolution of Cow's Milk Allergy

NCT02719405
View directory record Official record
Conditions
Milk Allergy
Interventions
Lactobacillus GG, Extensively Hydrolyzed Casein Formula, Amino Acid Formula
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 120 Days
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

NCT06387186
View directory record Official record
Conditions
Refractory Epilepsy, Drug Resistant Epilepsy
Interventions
Leucine-Enriched Essential Amino Acid powder
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
2 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

D-cycloserine and Treatment of Feeding Disorders

NCT01923896
View directory record Official record
Conditions
Feeding Disorders, Specific Phobia
Interventions
Behavioral Intervention, d-cycloserine (DCS), Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Months to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 26, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

NCT00540514
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Albumin-bound paclitaxel, Paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
31
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 26, 2026, 10:32 AM EDT